Ethan Harris

Ethan Harris

Auto-generated profile, based on publicly available information

Ethan Harris

University of Illinois Chicago 12 Chicago, IL

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2022 in Oncogene
Verified
Journal Article
Closed access
PDF file
MRMalini Rammohan
Malini Rammohan
EHEthan Harris
Ethan Harris
RBRahul Bhansali
Rahul Bhansali
EZEmily Zhao
Emily Zhao
LLLoretta S. Li
Loretta S. Li
JCJohn D. Crispino
John D. Crispino

1 March 2020 in Advances in Radiation Oncology
Verified
Journal Article
Open access
DKDaniel W. Kim
Daniel W. Kim
GLGrace Lee
Grace Lee
MLMiranda B. Lam
Miranda B. Lam
EHEthan J. Harris
Ethan J. Harris
ALAllen C. Lam
Allen C. Lam
RTRoy B. Tishler
Roy B. Tishler

5 December 2024 in Blood
Verified
Journal Article
Open access
QJQi Jin
Qi Jin
EHEthan Harris
Ethan Harris
JMJacquelyn A. Myers
Jacquelyn A. Myers
RMRashid Mehmood
Rashid Mehmood
ACAnitria Cotton
Anitria Cotton
JCJohn D. Crispino
John D. Crispino
There are only a few options for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), thus, this is a major area of unmet medical need. In this study, we reveal that the inclusion of a poison exon in RBM39, which could be induced by both CDK9 or CDK9 independent cyclin-dependent kinases, mitogen-activated protein kinases, glycogen synthase kinases, CDC-like kinases (CMGC) kinase inhibition, is recognized by the nonsense-mediated messenger RNA decay pathway for degradation. Targeting this poison exon in RBM39 with CMGC inhibitors led to protein downregulation and the inhibition of ALL growth, particularly in relapsed/refractory B-ALL. Mechanistically, disruption of cotranscriptional splicing by the inhibition of CMGC kinases, including DYRK1A, or inhibition of CDK9, which phosphorylate the C-terminal domain of RNA polymerase II (Pol II), led to alteration in the SF3B1 and Pol II association. Disruption of SF3B1 and the transcriptional elongation complex altered Pol II pausing, which promoted the inclusion of a poison exon in RBM39. Moreover, RBM39 ablation suppressed the growth of human B-ALL, and targeting RBM39 with sulfonamides, which degrade RBM39 protein, showed strong antitumor activity in preclinical models. Our data reveal that relapsed/refractory B-ALL is susceptible to pharmacologic and genetic inhibition of RBM39 and provide 2 potential strategies to target this axis.

27 October 2020 in Laryngoscope Investigative Otolaryngology
Verified
Journal Article
Open access
PDF file
EHEthan J. Harris
Ethan J. Harris
JHJulian Huang
Julian Huang
ECErin Carroll
Erin Carroll
ALAlarice C. Lowe
Alarice C. Lowe
NCNicole G. Chau
Nicole G. Chau
JLJochen Lorch
Jochen Lorch
Background Circulating tumors cells (CTCs) are considered an early step towards metastasis and have been linked to poor prognosis in several types of cancer. CTCs in squamous cell carcinoma of the head and neck (SCCHN) have an unclear role. Methods In this prospective study, patients with locally advanced or metastatic SCCHN had CTC counts assessed before starting systemic treatment using the CellSearch System. Select cases also had sequential CTC evaluation. Presence of CTCs was correlated with patient characteristics and outcomes. Results Forty‐eight patients enrolled, and 36 had evaluable clinical data and baseline CTC counts. Twenty‐five patients had locally advanced disease (LAD) and 11 had metastatic disease. ≥1 CTCs were detected in six patients with LAD (24%) and four with metastatic disease (36%). On univariate analysis, smoking was associated with CTCs. Conclusion CTCs are not associated with prognosis in patients with LAD and metastatic disease; however, they are present in this patient population, and ≥1 CTCs is associated with a history of smoking. Level of evidence 1b; individual prospective cohort study.

6 November 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
JLJochen H. Lorch
Jochen H. Lorch
KWKristine Wong
Kristine Wong
RTRoy B. Tishler
Roy B. Tishler
RHRobert I. Haddad
Robert I. Haddad
AOAnne O’NEill
Anne O’NEill
JSJennifer M Spangle
Jennifer M Spangle
Purpose: To determine the maximum tolerated dose (MTD) of the pan–class I PI3K inhibitor buparlisib (B) in combination with weekly cisplatin and radiotherapy (RT) among patients with locally advanced (LA) squamous cell cancer of the head and neck (SCCHN) and tobacco history. Patients and Methods: Patients with stage III/IV LA-SCCHN [American Joint Committee on Cancer (AJCC), Seventh Edition] and >10 pack-year tobacco use history were enrolled. Patients received B during a 2-week run-in phase and during chemoradiotherapy (CRT) consisting of standard 70 Gy of RT plus weekly cisplatin. An exploratory analysis of genomic sequencing was performed on biopsy specimens. Results: Twenty-three patients were enrolled {n = 17 at the MTD [B 40 mg daily and cisplatin (CDDP) 30 mg/m2/week]}. Ninety-one percent (21/23) had stage IV disease. Human papillomavirus (HPV) was detected in 15 of 18 cases with oral/oropharyngeal disease. The median follow-up was 23 months. Recurrence was detected in five patients among whom four had evaluable tumor samples. Fifty-percent (2/4) of patients with evaluable tumor samples were characterized by activation of the PI3K pathway. In five patients whose disease responded during the 2-week run-in phase with B alone, 3 of 4 with sequencing data showed loss-of-function mutations in either tumor necrosis factor receptor–associated factor 3 (TRAF3) or cylindromatosis lysine deubiquitinase (CYLD). Preclinical studies with mutations in TRAF3 or CYLD modeled via CRISPR/Cas9 knockout in HPV+ SCCHN cells demonstrate that loss of TRAF3 or CYLD may sensitize SCCHN cell lines to PI3K through mechanisms other than blocking the NF-κB pathway. Conclusions: Low-dose B with CRT was feasible and active in this high-risk cohort, although escalation to the standard weekly cisplatin dose of 40 mg/m2 was not possible. Our data suggest that TRAF3/CYLD-mutant SCCHN may be susceptible to PI3K inhibition with B, whereas PI3K pathway activation seemed to be associated with poor outcomes in this limited dataset.